Tocilizumab is an lnterleukin-6 inhibitor (IL-6i). IL-6i belongs to a class of medication called biologics or more specifically, biological disease modifying anti-rheumatic drugs (bDMARDs).
Biologics are small molecules that work by blocking certain parts of the immune system that cause inflammation in the body.
IL-6i targets and blocks natural substances called cytokines which causes inflammation in the body. This improves symptoms, reduces flares, slows disease progression and improves quality of life.
It may be used alone or together with other DMARDs.
